Skip to main content
BrainCited

Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease.

Madhuri Venigalla, Erika Gyengesi, Gerald Münch
Review Neural regeneration research 2015 161 件の引用
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'pmid\u003D26487830'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

研究タイプ
Review
対象集団
Alzheimer's disease patients
介入
Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease. None
比較対照
None
主要アウトカム
None
効果の方向
Positive
バイアスリスク
Unclear

Abstract

Alzheimer's disease is a progressive neurodegenerative disorder, characterized by deposition of amyloid beta, neurofibrillary tangles, astrogliosis and microgliosis, leading to neuronal dysfunction and loss in the brain. Current treatments for Alzheimer's disease primarily focus on enhancement of cholinergic transmission. However, these treatments are only symptomatic, and no disease-modifying drug is available for Alzheimer's disease patients. This review will provide an overview of the proven antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing effects of curcumin and apigenin and discuss the potential of these compounds for Alzheimer's disease prevention and treatment. We suggest that these compounds might delay the onset of Alzheimer's disease or slow down its progression, and they should enter clinical trials as soon as possible.

要約

It is suggested that curcumin and apigenin might delay the onset of Alzheimer′s disease or slow down its progression, and they should enter clinical trials as soon as possible.

Used In Evidence Reviews

Similar Papers